Patients with advanced head and neck squamous cell carcinoma (HNSCC) who progressed after platinum‐based therapy and heavily pretreated with M7824 (1200 mg, Q2W) showed a confirmed objective response rate of 13% per independent review committee (16% per investigator), which was more pronounced in HPV+ compared with PD‐L1−/+ patients. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.